Two working peptides, a few carriers, and nothing added for the label
No serious adverse events were attributed to AOD 9604 in any trial
Providers can start using the new E-codes in combination with the existing Z-codes beginning October 1, 2024
At the end of the month, we will conduct a thorough evaluation to review your results and discuss further steps
In D-galactose-induced aging mice, oral administration of the product significantly increased NAD+ levels in liver and adipose tissue, activated mitochondrial energy metabolism pathways, improved insulin sensitivity, lowered blood glucose and lipid levels, reduced visceral fat accumulation, and increased energy expenditure, alleviating fatigue and abnormal body weight associated with aging
Patient and family education regarding hypoglycemia management is crucial